MedicalResearch.com Interview with:
Anita Kohli, MS, MD
Clinician Investigator, Clinical Monitoring Research Program (CMRP)
Leidos Biomedical Research, Inc. formerly SAIC-Frederick, Inc.
National Institutes of Health Bethesda, MD 20892
Medical Research: What is the background for this study? What are the main findings?
Dr. Kohli: We previously treated 60 patients with sofosbuvir
and ribavirin for 24 weeks. Patients who relapsed after treatment were
offered re-treatment with another regimen of directly acting antivirals
alone. 13 patients who relapsed were treated with sofosbuvir and
ledipasvir for 12 weeks. All patients achieved SVR12. This is the first
report of re-treating patients who failed a regimen including sofosbuvir
with another regimen incorporating this same antiviral.
Medical Research: What should clinicians and patients take away from your report?
Dr. Kohli: Re-treatment of hepatitis C in patients who have failed previous DAA therapy is possible. However, resistance to hepatitis C
drugs is an evolving story and seems like quite different than with
HIV. It will continue to evolve with the introduction of new drugs and